INTRODUCTION: Effective vaccination strategies are required to combat future influenza
pandemics. Here we report the results of three independent clinical trials performed in …

The immunogenicity and reactogenicity of two influenza vaccines were evaluated in a
randomised, double-blind trial in north-east Italy during winter 2005–2006. Of 238 adult …

Background We analyzed data from a randomized controlled trial on the reactogenicity of 3
enhanced influenza vaccines compared with standard-dose (SD) inactivated influenza …

In a randomized, observer-blind, three-arm, parallel group, multi-centre trial including 386
elderly subjects in four countries, the immunogenicity and safety was studied of three …

Background In the elderly, traditional influenza inactivated vaccines are often only modestly
immunogenic, owing to immunosenescence. Given that adjuvantation is a means of …

MF59-adjuvanted seasonal trivalent inactivated (ATIV) vaccine licensed since 1997 and
MF59-adjuvanted pandemic H1N1 vaccines have been distributed to approximately 80M …

BACKGROUND: We hypothesized that low dose intradermal vaccination of the trivalent
influenza vaccine (TIV) delivered by the MicronJet600™(NanoPass Technologies, Israel) …

MF59 is a well-established, safe and potent vaccine adjuvant that has been licensed for
more than 13 years for use in an influenza vaccine focused on elderly subjects (Fluad® …

Background The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first
pandemic of the 21st century. Development of effective vaccines is a public health priority …

Cellular immunity is important for protection against the serious complications of influenza in
older adults. As it is unclear if newer influenza vaccines elicit greater cellular responses than …